CytoDyn Brass Hyped COVID Drug, Dumped Shares, Suit Says
Biotech company CytoDyn Inc. executives have been hit with a derivative suit in a Washington federal court, accusing the company of inflating its stock price by overhyping a purported COVID-19 treatment...To view the full article, register now.
Already a subscriber? Click here to view full article